Tozorakimab is a medication being studied as an additional treatment for people with Chronic Obstructive Pulmonary Disease (COPD). It is designed to help reduce the frequency of COPD flare-ups (exacerbations) in people who used to smoke. The medication is given alongside standard COPD treatments to see if it can provide better control of the disease symptoms and prevent worsening of the condition.

Standard of care refers to the usual medications and treatments that COPD patients typically receive, which may include inhaled bronchodilators and corticosteroids. In this study, all participants continue their regular COPD treatments while either receiving tozorakimab or placebo.

Chronic Obstructive Pulmonary Disease (COPD) – A progressive lung condition that causes breathing difficulties due to narrowed airways and damaged lung tissue. The disease typically develops over many years, mainly affecting the bronchi and air sacs in the lungs. COPD makes it increasingly difficult to breathe, particularly during physical activity, as the airways become inflamed and thickened. The condition is characterized by persistent respiratory symptoms, including shortness of breath, chronic cough, and increased mucus production. The disease causes the lungs to gradually lose their elastic quality and become less efficient at moving air in and out.